ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Autologous Cell Therapy Market, By Product Type, By Application, By Technology, By End User, By Geography
»óǰÄÚµå : 1671847
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀº 2025³â¿¡´Â 55¾ï 1,000¸¸ ´Þ·¯, 2032³â¿¡´Â 223¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 22.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 55¾ï 1,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 22.1% 2032³â °¡Ä¡ ¿¹Ãø 223¾ï ´Þ·¯
±×¸². ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â
Autologous Cell Therapy Market-IMG1

¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀº ÃÖ±Ù ¸î ³âµ¿¾È °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÚ°¡ ¼¼Æ÷ Ä¡·á´Â ȯÀÚ ÀÚ½ÅÀÇ ¸ö¿¡¼­ Áٱ⼼Æ÷³ª ´Ù¸¥ À¯ÇüÀÇ ¼¼Æ÷¸¦ äÃëÇÏ¿© ´Ù¾çÇÑ °úÁ¤À» ÅëÇØ º¯Çü ¶Ç´Â Áõ½Ä½ÃŲ ÈÄ µ¿ÀÏÇÑ È¯ÀÚ¿¡°Ô ÁÖÀÔÇÏ¿© Áúº´À» Ä¡·áÇÏ´Â °ÍÀÔ´Ï´Ù. ¾ÏÀ̳ª ½Å°æÁúȯ°ú °°Àº º¹ÀâÇÑ Áúº´À» ¸é¿ª¿ø¼º ¿ì·Á¸¦ ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·áÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀû Ä¡·á Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, µ¿Á¾ ¼¼Æ÷¿¡ ºñÇØ ÀÚ°¡ ¼¼Æ÷ÀÇ ¿ì¿ù¼º µîÀÌ ÇâÈÄ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª ½ÃÀå °³¹ß ¹× Á¦Á¶¿¡ µû¸¥ ³ôÀº ºñ¿ë°ú ±ÔÁ¦»óÀÇ ¹®Á¦°¡ ½ÃÀå ÁøÀÔ¿¡ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀº ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, Á¦Ç° °³¹ßÀ» ÃËÁøÇϱâ À§ÇÑ °ø°ø ¹× ¹Î°£ ±â¾÷ÀÇ ÅõÀÚ Áõ°¡, °³ÀÎ ¸ÂÃãÇü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë, º¹ÀâÇÑ Á¦Á¶ °øÁ¤, ¾ö°ÝÇÑ ±ÔÁ¦ Á¤Ã¥Àº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »õ·Î¿î ÀûÀÀÁõ¿¡ ´ëÇÑ ÀÚ°¡ ¼¼Æ÷ Ä¡·áÁ¦ÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» Æò°¡Çϱâ À§ÇÑ ´Ù¾çÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̸ç, Çõ½ÅÀûÀÎ Á¦Á¶ ±â¼ú °³¹ßÀº ±âÁ¸ ±â¾÷»Ó¸¸ ¾Æ´Ï¶ó ½Å±Ô ÁøÃâ±â¾÷µé¿¡°Ôµµ Å« ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ Àû¿ëÀ» È®´ëÇϱâ À§ÇØ Çмú ¿¬±¸ ±â°ü°ú Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ µî ÁÖ¿ä ±¹°¡ÀÇ ÇコÄɾî ÀÎÇÁ¶ó ¼ºÀå°ú ÇコÄɾî ÁöÃâ Áõ°¡·Î ÀÎÇØ À¯¸®ÇÑ ½ÃÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â Bristol Myers Squibb, Novartis, Novartis, Gilead Sciences, Kite Pharma, Celgene, Amgen, Takeda Pharmaceutical Industry, Merck KGaA, Bluebird Bio, Celyad Oncology, Adaptimmune Therapeutics, Allogene Therapeutics, Athersys, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå, Á¦Ç° À¯Çüº°, 2020³â-2032³â

Á¦5Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå, ¿ëµµº°, 2020³â-2032³â

Á¦6Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå, ±â¼úº°, 2020³â-2032³â

Á¦7Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â

Á¦8Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Autologous Cell Therapy Market is estimated to be valued at USD 5.51 Bn in 2025 and is expected to reach USD 22.30 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 22.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 5.51 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 22.10% 2032 Value Projection: USD 22.30 Bn
Figure. Autologous Cell Therapy Market Share (%), By Region, 2025
Autologous Cell Therapy Market - IMG1

The global autologous cell therapy market has been witnessing significant growth in the recent years. Autologous cell therapy involves the collection of stem cells or other types of cells from patient's own body, modifying or expanding them through various processes and infusing back to the same patient to treat diseases. It provides an alternative therapeutic approach to treat complex diseases like cancer and neurological disorders with minimal immunogenicity concerns. Rising prevalence of chronic diseases, growing demand for personalized medicine, and advantages of autologous cells over allogeneic cells are some key factors expected to propel demand for autologous cell therapies going forward. However, high costs associated with development and manufacturing along with regulatory challenges are major barriers to the market.

Market Dynamics:

The global autologous cell therapy market is driven by rising geriatric population vulnerable to develop chronic diseases, increasing investments from public and private players to expedite product development, and growing demand for personalized treatment options. However, high development costs, complex manufacturing processes, and stringent regulatory policies are projected to restrain the market growth during the forecast period. Various ongoing clinical trials evaluating efficacy and safety of autologous cell therapies for new indications and development of innovative manufacturing technologies present significant opportunities for existing as well as new market players. Key players are collaborating with academic research institutions to expand applications of these therapies. Asia Pacific presents lucrative market opportunities with growing healthcare infrastructure and increasing healthcare spending in major countries like China and India.

Key Features of the Study:

This report provides in-depth analysis of the global autologous cell therapy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autologous cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Bristol Myers Squibb, Novartis, Gilead Sciences, Kite Pharma, Celgene, Amgen, Takeda Pharmaceutical Company, Merck KGaA, Bluebird Bio, Celyad Oncology, Adaptimmune Therapeutics, Allogene Therapeutics, Athersys, Inc., BrainStorm Cell Therapeutics, and Sorrento Therapeutics

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autologous cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autologous cell therapy market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Autologous Cell Therapy Market, By Product Type, 2020-2032, (USD Bn)

5. Global Autologous Cell Therapy Market, By Application, 2020-2032, (USD Bn)

6. Global Autologous Cell Therapy Market, By Technology, 2020-2032, (USD Bn)

7. Global Autologous Cell Therapy Market, By End User, 2020-2032, (USD Bn)

8. Global Autologous Cell Therapy Market, By Region, 2020 - 2032, Value (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â